SCHEMBL5137905

SCHEMBL5137905

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1cccc(OCc2ccccc2)c1)CC1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 9/20 0.43
BCHE P06276 5/20 0.42
ALOX5 P09917 1/20 0.42
C5AR1 P21730 1/20 0.41
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
XBP1 P17861 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648532 0.94 C5AR1 (0.41) IGF1RBCHEALOX5C5AR1PPARG
SCHEMBL5134916 0.92 BCHE (0.40) IGF1RBCHEALOX5C5AR1PPARG
SCHEMBL5137356 0.92 MEN1 (0.45) C5AR1KMT2AMEN1ALDH1A1
SCHEMBL5135374 0.89 C5AR1 (0.40) C5AR1KMT2AMEN1
SCHEMBL648763 0.89 C5AR1 (0.40) IGF1RBCHEC5AR1KMT2AMEN1
SCHEMBL5137864 0.88 C5AR1 (0.44) BCHEC5AR1ALDH1A1HPGD
SCHEMBL5136024 0.88 C5AR1 (0.41) IGF1RBCHEC5AR1KMT2AMEN1
SCHEMBL5136497 0.88 C5AR1 (0.41) IGF1RC5AR1KMT2AMEN1ALDH1A1
SCHEMBL650496 0.87 C5AR1 (0.40) C5AR1KMT2AMEN1
SCHEMBL648304 0.87 C5AR1 (0.41) BCHEC5AR1KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed